▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / QCLS

QCLS — Q/C TECHNOLOGIES, INC.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1321834 ·
Last close
$3.94
Market Cap
$30.94M
52W High
$5.49
52W Low
$3.14
ADV30
585,432
Next earnings
—
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 0 -1,855,193 -1,242,777 38,291,383 1,127,619 17,571,777
Dec 2025 0 0 -3,714,248 -5,894,796 41,166,096 986,996 19,414,421
Sep 2025 0 0 -1,524,235 -2,811,388 37,231,786 6,904,185 22,911,396
Jun 2025 0 0 -1,872,623 -1,796,195 17,151,103 207,553 11,873,816

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,065,619
Investing CF
$-8,424,360
Financing CF
$18,303,821
CapEx
—
Dividends Paid
$-77,626
Buybacks
$0
EPS Diluted TTM
$-164.12
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-144,122,733
Inventory
—
Receivables
$18,200
ST Investments
$14,801,267
EBIT TTM
$-9,582,940
Pretax Income TTM
$-11,627,122
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -9,582,940 -11,627,122 41,166,096 19,414,421 — -9,065,619
Dec 2024 0 -8,660,188 -23,359,334 21,421,084 11,631,344 — -8,976,347
Dec 2023 0 -16,360,218 -3,999,950 17,862,270 5,492,698 — -12,980,625
Dec 2022 0 -15,282,763 -15,197,336 17,539,980 2,844,924 — -12,270,068

Peers — same industry

TickerNameMarket CapLastDaily %
VNRX VOLITIONRX LTD $24.49M $2.94 —
ONMD OneMedNet Corp $48.17M $0.88 —
AWHL Aspira Women's Health Inc. $19.79M $0.46 —
TRIB TRINITY BIOTECH PLC $13.10M $0.65 —
NYMXF NYMOX PHARMACEUTICAL CORP $12.29M $0.13 —

News headlines (Yahoo Finance, 1h cache)

Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors
2026-01-20 14:15 · Yahoo
Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives
2025-10-16 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →